Post-Approval Study of MelaFind

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by MELA Sciences, Inc.
Information provided by (Responsible Party):
MELA Sciences, Inc. Identifier:
First received: October 2, 2012
Last updated: February 1, 2015
Last verified: February 2015

The purpose of this study is to collect data to describe the real-world use and safety and effectiveness of MelaFind® in a post-approval clinical setting.

Condition Intervention
Device: MelaFind

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Post-Approval Study of MelaFind

Further study details as provided by MELA Sciences, Inc.:

Primary Outcome Measures:
  • Relative sensitivity comparing enrolling dermatologists after MelaFind use with enrolling dermatoligsts if MelaFind were not available [ Time Frame: 6 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To describe characteristics of patients and lesions with MelaFind, the experience of using MelaFind, distribution of test results, and details on biopsied lesions. [ Time Frame: 6 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 720
Study Start Date: November 2012
Estimated Study Completion Date: March 2018
Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: MelaFind
    The device is used when a dermatologist chooses to obtain additional information on atypical skin lesions for a decision to biopsy.
Detailed Description:

The primary objective of this study to test the hypothesis that, among eligible and evaluable lesions with central histological reference standard status melanoma or high-grade lesion, the relative sensitivity ρ comparing enrolling dermatologists after MelaFind use with enrolling dermatologists if MelaFind were not available is greater than 110%. This represents a clinically meaningful increase in sensitivity.

The secondary objectives of this study are to evaluate real-world use and safety and effectiveness of MelaFind in a clinical setting.


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

All patients of any age, race, ethnicity, or gender, presenting with pigmented skin lesions that that meet the Indications for Use and Lesion Inclusion and Exclusion Criteria, including signing the Informed Consent Form, are eligible to participate in this study. This single-arm study has one study group consisting of eligible lesions on eligible patients.

Up to six clinical sites in the US will participate in this study, one in each of the six states in which MelaFind is commercially available. Some of the sites will be located in urban settings, and some will be located in a suburban or rural setting. At least 50% of the sites will new, i.e., they did not participate in the MelaFind pivotal study. Some sites will be academic centers and some private practices.


Inclusion Criteria:

  • The lesion is pigmented (i.e., melanin, keratin, blood)
  • Clinical management of the lesion by the examining dermatologist is either biopsy of the lesion in toto, or 3-month follow-up of the lesion
  • The diameter of the pigmented area is between 2 and 22 millimeters
  • The lesion is accessible to the MelaFind hand-held imaging device
  • The patient, or a legally authorized representative, has consented to participate in the study and has signed the Informed Consent Form

Exclusion Criteria:

  • The patient has a known allergy to isopropyl alcohol
  • The lesion has been previously biopsied, excised, or traumatized
  • The skin is not intact (e.g., open sores, ulcers, bleeding)
  • The lesion is within 1 cm of the eye
  • The lesion is on mucosal surfaces (e.g., lips, genitals)
  • The lesion is on palmar hands
  • The lesion is on plantar feet
  • The lesion is on or under nails
  • The lesion is located on or in an area of visible scarring
  • The lesion contains foreign matter (e.g., tattoo, splinter, marker)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01700114

Contact: Natalie Tucker 914-591-3783 ext 723

United States, Colorado
AboutSkin Dermatology and DermSurgery Recruiting
Englewood, Colorado, United States, 80113
Contact: Jessica Sussman    303-756-7546      
Principal Investigator: Joel L. Cohen, MD         
United States, Florida
Dermatology Associates of Tallahassee Recruiting
Tallahassee, Florida, United States, 32308
Contact: Anna Green    850-877-4134      
Principal Investigator: Armand Cognetta, MD         
United States, Maryland
The Johns Hopkins University Recruiting
Baltimore, Maryland, United States, 21205
Contact: Sherry Leung    410-502-7546      
Principal Investigator: Timothy Wang, MD         
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Principal Investigator: Arthur Sober, MD         
United States, New Jersey
The Dermatology Group, P.C. Recruiting
Verona, New Jersey, United States, 07044
Contact: Johanni Villalona, CCRC, CMA    973-571-2121      
Principal Investigator: Robert Nossa, MD         
United States, Ohio
University Hospitals Case Medical Center Recruiting
Cleveland, Ohio, United States, 44106
Contact: Heather Tribout    216-844-1000      
Principal Investigator: Meg Gerstenblith, MD         
Sponsors and Collaborators
MELA Sciences, Inc.
  More Information

No publications provided

Responsible Party: MELA Sciences, Inc. Identifier: NCT01700114     History of Changes
Other Study ID Numbers: Protocol 20111
Study First Received: October 2, 2012
Last Updated: February 1, 2015
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by MELA Sciences, Inc.:
Pigmented Skin Lesions
Skin Cancer
MelaFind processed this record on March 26, 2015